VECTORAL PUBLISHING

Date of publication 09/01/2024, date of current version 09/01/2024.

*VECTORAL manuscript Identifier 11.01-5/VECTORAL.2022.PUB*

# THE IMPACT OF AXONAL TRANSPORT DISRUPTION AND CYTOSKELETAL ALTERATIONS ON NEURONAL INTEGRITY IN THE CONTEXT OF NEUROPATHIC PAIN

**IOANA MARINESCU[1], VLADIMIR KOVAčEVIć [2]**

[1]Department of Pharmacy, Universitatea Ovidius din Constanța, Bulevardul Mamaia, Constanța, 900527, Romania

[2]Department of Neurobiology, Universitatea Tehnică din Cluj-Napoca, Strada Constantin Daicoviciu, Cluj-Napoca, 400020, Romania.

Corresponding author: Marinescu, A.



**ABSTRACT** Neuropathic arises from injury or dysfunction of the somatosensory nervous system, characterized by persistent pain, hyperalgesia, and allodynia. A critical aspect of neuropathic pain pathophysiology involves disruptions in axonal transport and alterations in the cytoskeleton, which impact neuronal integrity and contribute to ongoing pain. Axonal transport, the process that moves organelles, proteins, and signaling molecules along axons, is essential for maintaining neuronal function and connectivity. Following nerve injury, disruptions in axonal transport occur due to damage to microtubules, motor proteins like kinesin and dynein, and impairments in mitochondrial movement, leading to deficits in cellular energy and axonal degeneration. Cytoskeletal alterations, including changes in microtubules, neurofilaments, and actin filaments, further compromise axonal stability and structural integrity, exacerbating neuronal injury and promoting the degeneration of affected neurons. These disruptions contribute to the loss of synaptic connectivity, the induction of neuroinflammation, and the sensitization of pain pathways. This review examines the mechanisms through which axonal transport disruption and cytoskeletal alterations contribute to neuronal damage in neuropathic pain. We focus on key molecular players such as tau, MAP kinases, and signaling pathways like JNK that influence cytoskeletal dynamics and axonal transport. Additionally, we discuss potential therapeutic strategies aimed at stabilizing the cytoskeleton and improving axonal transport to preserve neuronal function and alleviate chronic pain. Understanding these processes is essential for developing new approaches to protect neuronal integrity and manage the progression of neuropathic pain.

**INDEX TERMS** axonal transport, cytoskeletal alterations, JNK pathway, kinesin, microtubules, neuronal integrity, tau

## I. INTRODUCTION

Neuropathic pain is a chronic pain condition that arises as a result of injury or disease affecting the somatosensory nervous system. It is characterized by symptoms such as spontaneous pain, hyperalgesia (increased sensitivity to pain), and allodynia (pain due to normally non-painful stimuli). A significant contributor to the persistence of neuropathic pain is the degeneration and dysfunction of neurons, particularly those in the dorsal root ganglia (DRG) and spinal cord. Two interconnected cellular processes—axonal transport and cytoskeletal stability—are crucial for maintaining neuronal integrity and ensuring proper communication between neurons and their target cells. Disruptions in these processes following nerve injury can lead to neuronal degeneration, impair synaptic connectivity, and contribute to the persistence of pain.

Axonal transport is responsible for the bidirectional movement of organelles, proteins, and other cargoes along axons. It is driven by motor proteins such as kinesin, which moves cargo toward the axon terminal (anterograde transport), and dynein, which transports cargo back toward the cell body (retrograde transport). Microtubules serve as tracks for these motor proteins, and their integrity is essential for efficient transport. Following nerve injury, axonal transport can become impaired due to damage to microtubules, alterations in motor protein function, and disruptions in mitochondrial movement, which are crucial for providing energy to axons. The dysfunction of axonal transport can lead to the buildup

of damaged organelles and misfolded proteins, exacerbating neuronal stress and contributing to the loss of neuronal function over time.

The cytoskeleton, composed of microtubules, neurofilaments, and actin filaments, provides structural support to axons and plays a key role in maintaining their shape and function. Injury-induced alterations in the cytoskeleton, such as the destabilization of microtubules and changes in neurofilament organization, contribute to axonal degeneration and neuronal apoptosis. These structural changes can result in impaired synaptic transmission and reduced communication between neurons, thereby contributing to chronic pain states. Moreover, cytoskeletal alterations can activate intracellular signaling pathways that promote inflammation and further neuronal damage, such as the c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) pathways.

Neuroinflammation is a critical component in the persistence of neuropathic pain, and it is closely linked to both cytoskeletal changes and axonal transport disruption. Microglial cells, which are the resident immune cells of the central nervous system, become activated in response to neuronal damage and release pro-inflammatory cytokines such as TNF- and IL-1. These cytokines can exacerbate neuronal injury by disrupting cytoskeletal stability and impairing axonal transport mechanisms. The interplay between neuroinflammation, cytoskeletal damage, and axonal transport deficits forms a vicious cycle that perpetuates neuronal degeneration and sustains chronic pain.

This review explores the impact of axonal transport disruption and cytoskeletal alterations on neuronal integrity in the context of neuropathic pain. We examine the molecular mechanisms that underlie these changes, focusing on the role of motor proteins, microtubule-associated proteins (MAPs), and signaling pathways like JNK and MAPK that influence axonal stability. We also discuss therapeutic strategies aimed at stabilizing the cytoskeleton and restoring axonal transport, offering potential avenues for reducing neuronal damage and alleviating chronic pain. By understanding these mechanisms, it may be possible to develop targeted treatments that mitigate the progression of neuropathic pain and improve the quality of life for patients suffering from this chronic condition.

The role of motor proteins and microtubules in axonal transport is of particular interest, as their dysfunction can directly contribute to the progression of neuropathic pain. Microtubule-associated proteins (MAPs), such as tau and MAP1B, play crucial roles in stabilizing microtubules and regulating their interactions with motor proteins. Changes in the phosphorylation state of these MAPs following nerve injury can alter microtubule dynamics and impact transport efficiency. In addition, nerve injury can lead to alterations in mitochondrial motility along axons, affecting the energy supply required for maintaining neuronal function and further compromising neuronal health. Understanding the specific molecular changes that occur in these pathways could provide new targets for therapeutic intervention.

Axonal transport and cytoskeletal stability are essential for maintaining the structural and functional integrity of neurons, particularly following injury. Disruptions in these processes contribute to neuronal degeneration, synaptic disconnection, and the activation of neuroinflammatory pathways that underlie chronic neuropathic pain. By targeting the molecular mechanisms that regulate axonal transport and cytoskeletal dynamics, it may be possible to develop more effective therapeutic strategies for managing neuropathic pain and preventing its progression.

## II. AXONAL TRANSPORT: MECHANISMS AND DISRUPTION IN NEUROPATHIC PAIN

### A. THE ROLE OF MOTOR PROTEINS IN AXONAL TRANSPORT

Axonal transport is a highly regulated process that ensures the proper distribution of organelles, vesicles, proteins, and RNA throughout the axon. Kinesin and dynein are the primary motor proteins responsible for anterograde and retrograde transport, respectively. Kinesin moves vesicles, mitochondria, and other materials from the cell body to the axon terminal, supporting synaptic function and axonal maintenance. Dynein, on the other hand, is responsible for transporting signaling endosomes, growth factors, and damaged organelles back to the cell body for recycling and repair.

Following nerve injury, the function of these motor proteins can become impaired due to alterations in their expression or post-translational modifications. For example, the phosphorylation of dynein and kinesin by stress-activated kinases, such as JNK, can inhibit their transport activity, leading to the accumulation of cargoes and the disruption of axonal homeostasis. This impairment in transport can result in reduced delivery of essential materials to the axon terminal, contributing to synaptic dysfunction and neuronal degeneration. Additionally, dysregulated motor protein activity can impair the retrograde transport of neurotrophic signals, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are critical for neuronal survival and regeneration. The resulting decrease in trophic support can further exacerbate the degeneration of injured neurons and perpetuate chronic pain states.

### B. MICROTUBULE DAMAGE AND ITS IMPACT ON AXONAL TRANSPORT

Microtubules are the primary tracks along which axonal transport occurs, and their integrity is crucial for maintaining efficient transport. Microtubules are composed of tubulin dimers, and their stability is regulated by microtubule-associated proteins (MAPs), such as tau. Tau proteins stabilize microtubules by binding along their length, but hyperphosphorylation of tau following nerve injury can lead to its detachment from microtubules, causing microtubule destabilization. This detachment results in an increase in unbound tau, which can aggregate and contribute to cellular toxicity, further compromising axonal stability.

**TABLE 1.** Key Components of Axonal Transport and Cytoskeletal Stability in Neurons

| Component | Role in Neuronal Function | Impact of Dysfunction in Neuropathic Pain |
|---|---|---|
| Kinesin | Mediates anterograde transport of organelles, synaptic vesicles, and proteins toward axon terminals | Impaired kinesin function can result in the accumulation of damaged organelles in the cell body, contributing to neuronal stress and degeneration. |
| Dynein | Mediates retrograde transport of signaling endosomes, growth factors, and damaged organelles back to the cell body | Disruption in dynein function can impair the delivery of neurotrophic signals and promote the buildup of cellular debris, exacerbating neuronal damage. |
| Microtubules | Provide structural support and serve as tracks for motor proteins | Microtubule destabilization leads to impaired axonal transport and contributes to axonal degeneration and loss of synaptic connections. |
| Neurofilaments | Maintain axonal caliber and structural integrity | Alterations in neurofilament organization can weaken axonal structure, increasing susceptibility to injury and contributing to neuronal apoptosis. |

**TABLE 2.** Signaling Pathways Involved in Axonal Stability and Neuroinflammation

| Pathway | Role in Axonal Stability | Contribution to Neuropathic Pain |
|---|---|---|
| JNK Pathway | Regulates stress responses and axonal growth, affecting microtubule stability | Activation following nerve injury can lead to microtubule destabilization, contributing to axonal degeneration and neuronal apoptosis. |
| MAPK Pathway | Controls cellular responses to stress and inflammation, influencing axonal repair mechanisms | Chronic activation can promote neuroinflammation and sustain pain signaling by impairing axonal transport. |
| PI3K-Akt Pathway | Supports cell survival and axonal regeneration by modulating cytoskeletal dynamics | Dysregulation can impair regenerative responses in injured neurons, leading to prolonged axonal damage and pain. |

**TABLE 3.** Functions and Impairment of Motor Proteins in Neuropathic Pain

| Motor Protein | Type of Transport | Role in Neuronal Function | Impact of Impairment in Neuropathic Pain |
|---|---|---|---|
| Kinesin | Anterograde transport | Delivers vesicles, mitochondria, and proteins to the axon terminal, supporting synaptic activity | Impairment can lead to synaptic dysfunction and energy deficits in distal axonal regions, contributing to neurodegeneration. |
| Dynein | Retrograde transport | Returns signaling endosomes, growth factors, and damaged organelles to the cell body for recycling | Disruption results in the accumulation of damaged components and reduced delivery of neurotrophic signals, promoting neuronal apoptosis. |

The destabilization of microtubules impairs the ability of motor proteins to move along axons, leading to transport deficits. This can result in the accumulation of organelles, such as mitochondria, and the formation of axonal swellings, which are often observed in neuropathic pain models. The impaired transport of mitochondria is particularly detrimental, as it leads to energy deficits within axons, further exacerbating neuronal injury. The inability to effectively transport mitochondria to areas of high energy demand can lead to localized ATP shortages, contributing to synaptic dysfunction and the failure of ion pumps that are critical for maintaining neuronal excitability.

The breakdown of microtubule integrity is not only associated with impaired transport but also with the activation of intracellular stress pathways. Microtubule destabilization can activate the JNK pathway, which has been shown to contribute to axonal degeneration and neuronal apoptosis. The activation of JNK following microtubule damage can promote the expression of pro-apoptotic genes, leading to cell death and further loss of neuronal connectivity. Targeting microtubule stability through the modulation of tau phosphorylation or the use of microtubule-stabilizing agents, such as paclitaxel or epothilones, has been explored as a potential strategy for preserving axonal transport and reducing neuronal damage. These approaches aim to restore the structural integrity of microtubules, allowing for improved transport efficiency and a reduction in neuropathic pain symptoms.

The disruption of axonal transport and microtubule stability is a major factor in the pathogenesis of neuropathic pain. Impaired transport due to motor protein dysfunction and microtubule destabilization leads to a cascade of cellular events, including the accumulation of damaged organelles, reduced energy supply, and activation of stress pathways that drive neuronal degeneration. Understanding the molecular underpinnings of these processes offers potential targets for therapeutic intervention aimed at restoring axonal function, preserving neuronal health, and ultimately alleviating chronic pain.

**TABLE 4.** Microtubule-Associated Changes Following Nerve Injury and Their Implications

| Microtubule Alteration | Regulating Protein | Effect on Axonal Transport | Implications in Neuropathic Pain |
|---|---|---|---|
| Tau Hyperphosphorylation | Tau kinase activity (e.g., GSK3) | Reduces tau binding to microtubules, leading to destabilization and impaired transport | Contributes to the accumulation of organelles and axonal degeneration, promoting chronic pain states. |
| Microtubule Depolymerization | Reduced MAP stabilization | Decreases the availability of stable tracks for motor proteins, impairing cargo transport | Leads to energy deficits in distal axon regions and the activation of pro-apoptotic pathways. |

## III. CYTOSKELETAL ALTERATIONS IN NEURONAL DEGENERATION

### A. ROLE OF MICROTUBULE DYNAMICS IN NEURONAL INTEGRITY

Microtubules provide structural support to axons and are critical for maintaining axonal shape and function. They undergo dynamic remodeling through the processes of polymerization and depolymerization, which are essential for axonal growth and repair. Microtubule dynamics are regulated by a balance between stabilizing and destabilizing forces, including the activity of microtubule-associated proteins (MAPs) such as tau. The regulated assembly and disassembly of microtubules allow for the adaptability of axons during development and after injury, enabling repair and the maintenance of synaptic connections.

However, following nerve injury, the balance between microtubule stability and dynamics is often disrupted. The increased activity of kinases, such as JNK and p38 MAPK, can promote the phosphorylation of MAPs, leading to microtubule instability and axonal degeneration. Hyperphosphorylation of tau and other MAPs results in their detachment from microtubules, causing the depolymerization of microtubule structures and impairing their function as tracks for axonal transport. This loss of structural integrity weakens the axon's ability to support proper transport and resist mechanical stress, thereby contributing to neuronal damage.

The loss of microtubule stability can trigger retrograde signaling pathways that lead to neuronal apoptosis. For example, the disruption of microtubule integrity can activate the c-Jun N-terminal kinase (JNK) pathway, which promotes the expression of pro-apoptotic genes and contributes to neuronal death. The activation of JNK results in the transcription of genes involved in cell death pathways, further amplifying neuronal injury. This process is particularly relevant in the dorsal root ganglia (DRG) and spinal cord, where axonal degeneration is closely associated with the persistence of neuropathic pain. The impairment of microtubule dynamics following nerve injury thus represents a critical mechanism driving both structural and functional degeneration of neurons in chronic pain conditions.

### B. NEUROFILAMENT DISRUPTION AND AXONAL DEGENERATION

Neurofilaments are intermediate filaments that provide structural stability to axons and play a role in regulating axonal diameter, which influences the speed of nerve conduction. They are composed of three subunits—light (NF-L), medium (NF-M), and heavy (NF-H) chains—that form a scaffold within the axon. This scaffold not only supports the structural integrity of the axon but also maintains the optimal spacing required for the efficient conduction of action potentials.

Following nerve injury, neurofilament phosphorylation can become dysregulated, leading to changes in their assembly and organization. This abnormal phosphorylation can result in the aggregation of neurofilaments, causing axonal beading and swelling, which are characteristic features of degenerating axons in neuropathic pain models. The aggregation and misalignment of neurofilaments disrupt the normal architecture of the axonal cytoskeleton, contributing to the breakdown of axonal integrity.

Disruption of neurofilament organization impairs axonal transport by creating physical barriers within the axon that interfere with the movement of motor proteins and their cargoes. This further contributes to axonal degeneration and the loss of neuronal connectivity, as the buildup of cellular debris and damaged organelles exacerbates neuronal stress. The impaired transport and organization of neurofilaments hinder the repair processes that are crucial for axonal regeneration after injury, thereby sustaining the progression of neuropathic pain.

Strategies aimed at modulating neurofilament phosphorylation have been investigated as potential therapeutic approaches to preserve axonal structure and prevent the progression of neuropathic pain. Compounds that inhibit abnormal kinase activity or enhance phosphatase activity could help restore normal neurofilament organization and maintain axonal integrity. Additionally, targeting the molecular pathways that regulate neurofilament assembly may improve axonal stability and slow the degeneration associated with chronic pain states.

Both microtubule dynamics and neurofilament organization are essential for the structural integrity and function of neurons. Their dysregulation following nerve injury plays a critical role in the pathogenesis of neuropathic pain by promoting axonal degeneration, disrupting transport processes, and activating pro-apoptotic pathways. Therapeutic approaches aimed at stabilizing these cytoskeletal components may offer new opportunities for preserving neuronal health and reducing the burden of chronic pain.

## IV. THERAPEUTIC APPROACHES TO RESTORE AXONAL TRANSPORT AND CYTOSKELETAL STABILITY

**TABLE 5.** Microtubule Dynamics and Their Disruption in Neuropathic Pain

| Regulatory Factor | Role in Microtubule Dynamics | Effect of Dysregulation | Implications in Neuropathic Pain |
|---|---|---|---|
| Tau (Microtubule-associated protein) | Stabilizes microtubules by binding along their length | Hyperphosphorylation leads to detachment from microtubules, causing instability | Contributes to axonal degeneration and impaired transport |
| JNK (c-Jun N-terminal kinase) | Regulates stress responses, including phosphorylation of MAPs | Activation leads to increased MAP phosphorylation, destabilizing microtubules | Promotes neuronal apoptosis through pro-apoptotic gene expression |
| p38 MAPK | Modulates inflammatory responses and microtubule dynamics | Enhances the phosphorylation of microtubule-associated proteins, leading to microtubule disassembly | Contributes to inflammatory signaling and structural degeneration in neurons |

**TABLE 6.** Effects of Neurofilament Dysregulation on Axonal Structure and Function

| Neurofilament Component | Role in Axonal Stability | Impact of Dysregulation | Consequences in Neuropathic Pain |
|---|---|---|---|
| NF-L (Light Chain) | Forms the core of neurofilament structures, contributing to axonal diameter | Abnormal phosphorylation leads to aggregation and disruption of axonal architecture | Impairs axonal transport, leading to neurodegeneration |
| NF-M (Medium Chain) | Regulates interactions between neurofilaments and axonal cytoskeleton | Dysregulation results in altered neurofilament spacing, impacting nerve conduction speed | Reduces nerve signaling efficiency, contributing to persistent pain |
| NF-H (Heavy Chain) | Supports axonal structural integrity and tensile strength | Hyperphosphorylation leads to abnormal accumulation and axonal beading | Associated with structural breakdown and impaired repair mechanisms |

### *A. MICROTUBULE-STABILIZING AGENTS*

Microtubule-stabilizing agents, such as taxol (paclitaxel) and epothilones, have been explored for their potential to enhance microtubule stability and support axonal transport in the context of nerve injury. These agents work by promoting the polymerization of microtubules, preventing their depolymerization, and supporting the structural integrity of axons. Taxol binds to microtubules and stabilizes them, thereby reducing microtubule dynamics and protecting axons from degeneration. In preclinical models, microtubule-stabilizing drugs have shown promise in reducing axonal degeneration and alleviating pain behaviors by preserving the axonal cytoskeleton and improving transport efficiency. However, their use is limited by potential side effects, such as neurotoxicity and immunosuppression, highlighting the need for more selective compounds that can target microtubule stability without affecting other cellular functions.

The development of novel microtubule-stabilizing agents that selectively target neurons offers a potential solution to these challenges. These agents could be designed to enhance the stability of microtubules specifically within injured neurons, thereby reducing the risk of systemic side effects. Additionally, combining microtubule-stabilizing drugs with other therapeutic approaches that enhance autophagic clearance of damaged cellular components may provide a synergistic effect, further supporting neuronal health and reducing the progression of neuropathic pain.

### *B. TARGETING MOTOR PROTEIN FUNCTION AND SIGNALING PATHWAYS*

Modulating the activity of motor proteins through the inhibition of stress-activated kinases has been investigated as a means to restore axonal transport. Stress-activated kinases, such as c-Jun N-terminal kinase (JNK), play a role in the phosphorylation of motor proteins like dynein and kinesin, which can impair their transport function. JNK inhibitors have shown potential in preclinical studies by reducing the phosphorylation of these motor proteins, thereby enhancing their ability to move along microtubules and transport essential cargoes. Improved axonal transport can result in better delivery of mitochondria, synaptic vesicles, and growth factors, which are critical for neuronal survival and synaptic function.

Additionally, targeting pathways that regulate microtubule-associated proteins, such as the tau kinases GSK-3$\beta$ (glycogen synthase kinase-3 beta) and CDK5 (cyclin-dependent kinase 5), offers a potential strategy for maintaining microtubule stability and supporting axonal transport. GSK-3$\beta$ inhibitors, for example, can reduce the hyperphosphorylation of tau, thereby stabilizing microtubules and preventing their breakdown. This approach aims to preserve the structural integrity of microtubules, allowing motor proteins to function more efficiently and enhancing the overall health of injured neurons. Such strategies have been particularly promising in reducing tau-related toxicity and improving axonal transport in animal models of neurodegeneration and chronic pain.

**TABLE 7.** Microtubule-Stabilizing Agents in Neuropathic Pain Treatment

| Agent | Mechanism of Action | Therapeutic Effects | Limitations |
|---|---|---|---|
| Taxol (Paclitaxel) | Binds to and stabilizes microtubules, preventing their depolymerization | Reduces axonal degeneration and improves transport of essential organelles | Neurotoxicity and potential for peripheral neuropathy |
| Epothilones | Promote microtubule polymerization, enhancing stability | Show promise in preclinical models for reducing pain behaviors and supporting axonal integrity | Risk of side effects due to systemic administration |
| Novel Neuron-Selective Stabilizers | Target microtubule stabilization specifically in neurons | Potential to provide neuroprotection with reduced systemic toxicity | Currently under investigation in preclinical studies |

**TABLE 8.** Targeting Motor Proteins and Signaling Pathways in Neuropathic Pain

| Therapeutic Approach | Target | Mechanism and Effects | Current Challenges |
|---|---|---|---|
| JNK Inhibitors | Inhibition of JNK-mediated phosphorylation of motor proteins | Enhances the function of dynein and kinesin, improving axonal transport | Potential off-target effects on other cellular stress responses |
| GSK-3$\beta$ Inhibitors | Reduction of tau hyperphosphorylation | Stabilizes microtubules, reducing tau-induced aggregation and supporting axonal transport | Requires precise dosing to avoid adverse effects on other signaling pathways |
| CDK5 Inhibitors | Modulation of CDK5 activity to regulate MAPs | Prevents the destabilization of microtubules and supports neuronal survival | Needs further development for specific targeting in neurons |

### C. NEUROPROTECTIVE APPROACHES AND MITOCHONDRIAL SUPPORT

Given the importance of mitochondrial transport for providing energy to injured axons, strategies that enhance mitochondrial function are critical for supporting neuronal survival. Mitochondria supply the ATP required for active transport processes, synaptic function, and the maintenance of ion gradients across neuronal membranes. Thus, the impairment of mitochondrial transport can lead to energy deficits, exacerbating neuronal damage and contributing to the persistence of neuropathic pain. Approaches that enhance mitochondrial biogenesis, improve mitochondrial quality control, and support their transport along axons have been studied as potential therapies.

Compounds that promote mitochondrial biogenesis, such as coenzyme Q10, PGC-1$\alpha$ (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) activators, and nicotinamide riboside, can enhance the production of new, healthy mitochondria, thereby improving cellular energy levels. These agents have demonstrated potential in reducing oxidative stress and improving mitochondrial function in neuronal models of injury. In addition, molecules like MitoQ (a mitochondria-targeted antioxidant) have been investigated for their ability to reduce oxidative damage within mitochondria, thus supporting their function and viability.

By enhancing mitochondrial movement along axons, these approaches may help to alleviate energy deficits and support neuronal repair processes in the context of neuropathic pain. Combining mitochondrial support strategies with microtubule stabilizers and motor protein modulators could provide a comprehensive approach to improving axonal health, reducing neuronal degeneration, and ultimately alleviating chronic pain symptoms.

The restoration of axonal transport and cytoskeletal stability represents a promising avenue for the treatment of neuropathic pain. By targeting the underlying mechanisms of neuronal degeneration, such as impaired microtubule dynamics, motor protein dysfunction, and mitochondrial transport deficits, these therapeutic approaches aim to reduce pain symptoms and promote long-term neuronal health.

## V. CONCLUSION

Disruptions in axonal transport and alterations in the cytoskeleton play a central role in the progression of neuropathic pain and neuronal degeneration. Damage to microtubules and impairments in motor protein function lead to transport deficits, energy shortages, and the accumulation of cellular stress, which contribute to neuronal injury. The inability to efficiently transport essential organelles, such as mitochondria, results in localized ATP deficits, exacerbating neuronal damage and diminishing the axon's ability to maintain ion gradients critical for nerve signal transmission. The subsequent accumulation of misfolded proteins and damaged organelles triggers stress response pathways, further amplifying neuronal degeneration.

Cytoskeletal alterations, including changes in microtubule stability and neurofilament organization, further compromise axonal integrity and drive the loss of synaptic connectivity. Microtubule destabilization, often due to the hyperphosphorylation of microtubule-associated proteins like tau, impairs the movement of motor proteins, contributing to the accumulation of cellular debris within the axon. This leads to the formation of axonal swellings, a hallmark of neuropathic pain models. Similarly, dysregulated neurofilament phosphorylation can disrupt the organization of these intermediate filaments, leading to structural abnormalities in axons that impede the efficient conduction of nerve impulses.

Understanding the molecular mechanisms that underlie these changes provides a basis for developing targeted ther-

apies aimed at stabilizing the cytoskeleton and restoring axonal transport. Therapeutic strategies that include the use of microtubule-stabilizing agents, such as taxol and epothilones, as well as inhibitors of stress-activated kinases like JNK, offer potential avenues for improving axonal transport and maintaining neuronal structure. Additionally, approaches that support mitochondrial function and biogenesis, such as PGC-1$\alpha$ activators and antioxidants like coenzyme Q10, can alleviate energy deficits and reduce oxidative damage within axons, further supporting neuronal survival.

Such strategies hold promise for preserving neuronal function, reducing chronic pain, and improving the quality of life for patients suffering from neuropathic conditions. By addressing the fundamental processes that contribute to neuronal degeneration, these approaches offer a more effective means of managing chronic pain than current symptomatic treatments. Ultimately, advances in our understanding of axonal transport and cytoskeletal dynamics will be key to unlocking new therapeutic options for neuropathic pain and related neurodegenerative conditions.[1]–[27]

## VECTORAL PUBLISHING POLICY

*VECTORAL maintains a strict policy requiring authors to submit only novel, original work that has not been published previously or concurrently submitted for publication elsewhere. When submitting a manuscript, authors must provide a comprehensive disclosure of all prior publications and ongoing submissions. VECTORAL prohibits the publication of preliminary or incomplete results. It is the responsibility of the submitting author to secure the agreement of all coauthors and obtain any necessary permissions from employers or sponsors prior to article submission. The VECTORAL takes a firm stance against honorary or courtesy authorship and strongly encourages authors to reference only directly relevant previous work. Proper citation practices are a fundamental obligation of the authors. VECTORAL does not publish conference records or proceedings.*

## VECOTORAL PUBLICATION PRINCIPLES

Authors should consider the following points:

1) To be considered for publication, technical papers must contribute to the advancement of knowledge in their field and acknowledge relevant existing research.
2) The length of a submitted paper should be proportionate to the significance or complexity of the research. For instance, a straightforward extension of previously published work may not warrant publication or could be adequately presented in a concise format.
3) Authors must demonstrate the scientific and technical value of their work to both peer reviewers and editors. The burden of proof is higher when presenting extraordinary or unexpected findings.
4) To facilitate scientific progress through replication, papers submitted for publication must provide sufficient information to enable readers to conduct similar experiments or calculations and reproduce the reported results. While not every detail needs to be disclosed, a paper must contain new, usable, and thoroughly described information.
5) Papers that discuss ongoing research or announce the most recent technical achievements may be suitable for presentation at a professional conference but may not be appropriate for publication.

## References

[1] A. Bell and R. Lewis, "The role of ion channels in epilepsy: Mechanisms and potential therapies," *Epilepsy Research*, vol. 116, pp. 95–107, 2015.
[2] D. Shen, W. Wu, J. Liu, *et al.*, "Ferroptosis in oligodendrocyte progenitor cells mediates white matter injury after hemorrhagic stroke," *Cell death & disease*, vol. 13, no. 3, p. 259, 2022.
[3] J. Clark and E. White, *Cellular Pathways in Neurodegeneration: Molecular Insights*, 1st. Berlin, Germany: Springer, 2011.
[4] O. Ford and I. Harris, "Inflammatory pathways in parkinson's disease: The role of microglia," *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 60, pp. 52–60, 2015.
[5] W. Chen, X. Wang, Q. Sun, *et al.*, "The upregulation of nlrp3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (tet2) contributed to diabetic neuropathic pain in mice," *Journal of Neuroinflammation*, vol. 19, no. 1, p. 302, 2022.
[6] S. Harrison and J. Davies, "Microglia activation in the pathogenesis of multiple sclerosis," *Frontiers in Neurology*, vol. 3, p. 43, 2012.
[7] P. Howard and A. Cooper, "Mechanisms of cellular stress in neurodegenerative diseases," *Cell Stress & Chaperones*, vol. 21, no. 5, pp. 709–720, 2016.
[8] Y. Ding, L. Hu, X. Wang, *et al.*, "The contribution of spinal dorsal horn astrocytes in neuropathic pain at the early stage of eae," *Neurobiology of Disease*, vol. 175, p. 105 914, 2022.
[9] D. Knight and M. Foster, *Cell Signaling in Neurological Disorders*, 2nd. New York, NY, USA: Wiley, 2014.
[10] K. Mason and J. Taylor, "Therapeutic approaches targeting synaptic dysfunction in autism," in *Proceedings of the International Conference on Neuroscience*, Paris, France, 2013, pp. 89–96.
[11] Q. Sun, T. Hu, Y. Zhang, *et al.*, "Irg1/itaconate increases il-10 release to alleviate mechanical and thermal hypersensitivity in mice after nerve injury," *Frontiers in Immunology*, vol. 13, p. 1 012 442, 2022.
[12] E. Murphy and H. Scott, "The role of mitochondrial dynamics in parkinson's disease," *Molecular Neurobiology*, vol. 49, no. 3, pp. 945–957, 2014.
[13] M. King and L. Bennett, "Oxidative stress in neurodegenerative diseases: Mechanisms and therapeutic strategies," *Brain Research Bulletin*, vol. 95, pp. 1–13, 2013.

[14] T. Russell and S. Gray, "Autophagy dysregulation in huntington's disease: Mechanisms and interventions," *Nature Neuroscience*, vol. 15, no. 10, pp. 1317–1325, 2012.

[15] T. Hu, Q. Sun, Y. Gou, *et al.*, "Salidroside alleviates chronic constriction injury-induced neuropathic pain and inhibits of txnip/nlrp3 pathway," *Neurochemical Research*, pp. 1–10, 2022.

[16] E. Stewart and J. Lee, "Mechanisms of synaptic degeneration in alzheimer's and parkinson's diseases," *Journal of Molecular Neuroscience*, vol. 50, no. 2, pp. 193–204, 2013.

[17] N. Thompson and W. Evans, "Glutamate signaling and excitotoxicity in neurodegeneration," *Neurobiology of Disease*, vol. 88, pp. 1–9, 2016.

[18] J. Liu, D. Shen, C. Wei, *et al.*, "Inhibition of the lrrc8a channel promotes microglia/macrophage phagocytosis and improves outcomes after intracerebral hemorrhagic stroke," *Iscience*, vol. 25, no. 12, 2022.

[19] M. Phillips and V. Edwards, "Neuroinflammation and tau pathology in alzheimer's disease," *Journal of Neuroinflammation*, vol. 11, p. 102, 2014.

[20] R. Walker and T. Hughes, "Endoplasmic reticulum stress in neuronal injury and repair," *Journal of Cellular Neuroscience*, vol. 42, no. 1, pp. 57–68, 2010.

[21] W. Chen, T. Lan, Q. Sun, *et al.*, "Whole genomic dna methylation profiling of cpg sites in promoter regions of dorsal root ganglion in diabetic neuropathic pain mice," *Journal of Molecular Neuroscience*, vol. 71, no. 12, pp. 2558–2565, 2021.

[22] L. Wright and S. Williams, "Advances in understanding glial cell function in cns disorders," in *Annual Conference of the European Society for Neuroscience*, Madrid, Spain, 2011, pp. 45–52.

[23] C. Watson and H. Mitchell, *Fundamentals of Neurodegenerative Diseases: A Molecular Perspective*, 1st. Boca Raton, FL, USA: CRC Press, 2012.

[24] C. Wei, Z. Xiao, Y. Zhang, *et al.*, "Itaconate protects ferroptotic neurons by alkylating gpx4 post stroke," *Cell Death & Differentiation*, pp. 1–16, 2024.

[25] R. Young and C. Morgan, "Calcium dysregulation in als: Pathophysiology and therapeutic approaches," *Neuroscience*, vol. 278, pp. 1–12, 2014.

[26] E. Clarkson and G. Adams, "Protein misfolding and aggregation in amyotrophic lateral sclerosis," *Neurotherapeutics*, vol. 13, no. 3, pp. 624–632, 2016.

[27] L. Peterson and B. Moore, "Neurovascular dysfunction in alzheimer's disease: A focus on blood-brain barrier integrity," *Journal of Cerebral Blood Flow & Metabolism*, vol. 37, no. 3, pp. 754–768, 2017.